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9JZ, United Kingdom; 2Translational Pharmacology, Department of Disease Biology, Astra Zeneca, SE-151 85 Södertälje, Sweden;
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The persistence of new memory traces in the hippocampus, encoded following appropriate activation of
glutamatergic receptors and the induction of synaptic plasticity, can be influenced by heterosynaptic activation of
neuromodulatory brain systems. We therefore investigated the effects of a hippocampus-specific blockade of
dopamine D1/D5 receptors on the persistence of spatial memory encoded in one trial using a delayed
matching-to-place (DMP) task in a watermaze in which rats learn a new escape location each day. A within-subjects
design was used such that both short (20 min) and long (6 h) retention intervals, and both drug (SCH23390, a
D1/D5 receptor antagonist) and vehicle (aCSF) infusions were tested on different days in the same animals. Bilateral
intrahippocampal infusion of SCH23390 (5 µg in 1 µL per side) prior to trial 1 (encoding) caused a differential
impairment as a function of memory delay—with no effect during trial 2 (memory retrieval) after a 20-min interval,
but a block of memory at 6 h. Further experiments revealed that infusion of SCH23390 immediately after trial 1 had
no effect on retention 6 h later, and the poor memory seen at long retention intervals when the drug was present at
encoding was not due to a state-dependent failure of retrieval. These results suggest that activation of D1/D5
receptors during memory encoding is necessary for the formation of a persistent memory trace in the hippocampus.
The complementary effects of D1/D5 receptor blockade on the persistence of LTP and the duration of memory are
consistent with the idea that changes in synaptic strength underlie memory.
The persistence of memory encoded by the hippocampal forma-
tion is subject to heterosynaptic neuromodulatory signals from a
number of cortical and subcortical structures. The hippocampus
receives dopaminergic projections from mesolimbic structures
such as the ventral tegmental area (VTA) and substantia nigra
(Carter and Fibiger 1977; Scatton et al. 1980; Swanson 1982; Gas-
barri et al. 1994a,b). These inputs may provide one neuromodu-
latory signal that could influence hippocampal memory, both in
rodents (for review, see Gasbarri et al. 1997; Jay 2003) and in
humans (e.g., Wittmann et al. 2005). The modulatory effect of
dopamine, particularly under circumstances of novelty (see Lis-
man and Grace 2005), could give rise to either a selective
strengthening of hippocampal memory traces or to an alteration
in the persistence of such traces (or some combination of both
effects). In the second case, neuromodulation acting at or around
the time of learning might affect the process of “cellular consoli-
dation” (Dudai and Morris 2001). Such modulation would be
consistent with the known effects of activation of dopaminergic
metabotropic receptors on postsynaptic intracellular signal-
transduction pathways.
Within this general framework, it is of importance to ask
about the conditions in which dopaminergic neurons are acti-
vated. Single-unit recording studies have revealed that burst fir-
ing of dopaminergic neurons is increased by unexpected reward
and in association with stimuli that predict the imminent arrival
of reward; such firing is also reduced when an expected reward is
omitted (e.g., Mirenowicz and Schultz 1994; Schultz and Dickin-
son 2000). These observations fit with computational models
that assign a key role for dopamine neurons in signaling any
discrepancy between predicted and received reward (Montague
et al. 1996). However, the firing rates of ventral tegmental area
dopaminergic neurons are also increased by exposure to novel
stimuli (Steinfels et al. 1983; Ljungberg et al. 1992). Thus, while
the role in reward processing is now well established for the stria-
tum, dopamine may have diverse functions that depend on the
brain region in which its release occurs. The focus of the present
work is its impact on hippocampal function. The observations
that hippocampal lesions disrupt the detection of certain kinds
of mismatch between stored and incoming information (Thinus-
Blanc et al. 1991; Fyhn et al. 2002), and that haemodynamic
activation of the human hippocampus is seen during the obser-
vation of novel stimuli (Tulving et al. 1994), collectively support
the suggestion that this brain area is involved in the computation
of novelty via “comparator” circuitry (Gray and McNaughton
2000; Vinogradova 2001). Other brain areas also detect other
kinds of novelty (Aggleton and Brown 1999). Once information
has been identified as novel, a signal may be carried from the
hippocampus (or other brain areas) through a polysynaptic path-
way (involving the subiculum, nucleus accumbens, and ventral
pallidum) to the VTA (see Lisman and Grace 2005). The novelty-
associated firing of dopaminergic VTA neurons could then lead
to dopamine release in various forebrain regions, including feed-
back regulation of the hippocampus itself.
What might be the impact of dopamine release in hippo-
campus? There is growing physiological evidence for dopamin-
ergic involvement in the late, protein synthesis-dependent phase
of long-term potentiation (Frey et al. 1990, 1991; Matthies et al.
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1997; Swanson-Park et al. 1999; O’Carroll and Morris 2004) and
in local dendritic protein synthesis (Smith et al. 2005). However,
a small effect of dopamine D1/D5 receptor blockade on early-LTP
is commonly observed and dopamine D1/D5 receptor agonists
can enhance the magnitude of CA1 early-LTP (Otmakhova and
Lisman 1996) and dentate gyrus LTP in anesthetized rats, in-
duced using a weak tetanus (Kusuki et al. 1997). Brief exposure to
a novel environment can also facilitate the induction of CA1 LTP
by a subsequent weak tetanus; this facilitation is selectively
blocked by a D1/D5 receptor antagonist, and mimicked by the
application of an agonist (Li et al. 2003). It follows that, if LTP-
like potentiation is part of the mechanisms of memory trace for-
mation, dopamine release could modulate the persistence or the
strength of hippocampus-dependent memory, or have both ef-
fects.
Several rodent studies have directly implicated hippocampal
dopamine receptors in memory, commensurate with their in-
volvement in LTP. For example, intrahippocampal infusion of
D1 or D2 receptor agonists can improve retention in radial maze
working memory tasks (Packard and White 1991; Wilkerson and
Levine 1999), and systemic infusion of a D1/D5 agonist improves
spatial memory in aged mice (Bach et al. 1999). Conversely, in-
trahippocampal blockade of D1/D5 receptors can disrupt the
consolidation of inhibitory avoidance (Bernabeu et al. 1997).
While spatial reference memory in the watermaze is unaffected
by 6-hydroxydopamine infusion into the neostriatum (Hagan et
al. 1983), it is impaired by such infusions into the nigrostriatal
bundle or lateral ventricles (Whishaw and Dunnett 1985) or di-
rectly into the subiculum and adjacent CA1 (Gasbarri et al. 1996).
Genetic deletion of D1 receptors in mice can also impair spatial
memory (El-Ghundi et al. 1999). These studies are suggestive, but
the precise role of dopaminergic manipulations on strength ver-
sus persistence of memory has not been explicitly addressed.
Accordingly, in the experiments reported here we investi-
gated the impact of blockade of dopamine receptors in the hip-
pocampus with the D1/D5 receptor antagonist SCH23390 in a
delayed matching-to-place (DMP) task in the watermaze. The
DMP version of the watermaze (Steele and Morris 1999) is a re-
peated one-trial memory task that is very sensitive to hippocam-
pal dysfunction of various kinds and allows the use of within-
subject manipulations across successive days of training with the
inclusion of a variable memory delay. In this variant, the hidden
platform is always in a “novel” location on the first trial of each
day, and remains in a fixed location for the subsequent trials of
that day (i.e., trials 2, 3 and 4). Trial 2 serves as a memory retrieval
trial to investigate the strength or persistence of memory en-
coded in trial 1. Trials 3 and 4 serve only to sustain the win-stay
strategy of swimming back to the place in the pool where escape
has been possible most recently. The cycle of four trials repeats
across days. We hypothesized that dopaminergic neurons would
be activated by the unexpected reward of finding an escape plat-
form in a novel location during the daily first trial of this task.
This should in turn activate metabotropic D1/D5 receptors in the
hippocampus and so result in either an enhancement of memory
irrespective of the retention interval or an increase in the persis-
tence of memory for spatial information (or both).
Results
A series of three experiments was conducted, consisting of “pre-
training” on the DMP task (over 8 d), during which the win-stay
strategy was learned, followed by different drug-infusion and
memory-delay conditions during a further series of eight “test-
ing” days. As noted previously, the DMP task involves moving
the hidden platform between separate locations across days, with
varying intervals between trials 1 and 2 of each day (Fig. 1A). On
a given day, the platform is placed in a novel location and then
stays there for all four trials. In Experiment 1, addressing the
primary issue of memory strength vs. persistence, drug or vehicle
was infused 15 min prior to trial 1 of the day (Fig. 1B), with the
memory delay between trials 1 and 2 varying between 20 min
and 6 h. The interval between trials 2, 3, and 4 was always 30 sec
(spent on the escape platform). Experiment 2 was concerned
with the impact of drug treatment after encoding, and so in-
volved drug or vehicle being infused 15 min after trial 1 and a
single 6-h memory delay. In Experiment 3, to test for state-
dependent effects, drug or vehicle was infused 15 min before trial
1, and a second infusion—always of SCH23390—was made 15
min before trial 2. Performance was compared with that on in-
terleaved “no infusion” days during the testing sequence; a 6-h
ITI between trials 1 and 2 was again used throughout. Whereas
most watermaze studies plot performance across days (reference
memory experiments), the DMP procedure focuses on changes
within a day averaged across days.
Pretraining: Acquisition of the DMP task
During pretraining, all animals swam effectively using the usual
posture of forepaw inhibition and learned to search for the hid-
den platform in trial 1. They then found this location more
quickly on subsequent trials. Overall performance improved dur-
ing the first few days, typically reaching a stable asymptote by
day 4. Trial 1 was characterized by high escape latencies indicat-
ing the lack of knowledge of each day’s novel platform position,
but when placed back in the pool in trial 2, escape latencies were
substantially reduced—reflecting the repeated acquisition of one-
trial memory. Figure 2 shows the development of this matching-
to-place performance over the course of pretraining in Experi-
Figure 1. Experimental design. (A) Varied platform location and
memory delay across days. All experiments used the delayed matching-
to-place (DMP) protocol in the watermaze, in which four trials are given
each day; the platform position is fixed within a day, but moved to
different locations between days. Swim paths are circuitous in trial 1 of
each day, but the focus is on whether memory traces formed during this
trial persist with any detectable strength until trial 2, which is scheduled
after a variable delay. The point of trials 3 and 4 is to sustain the learned
win-stay strategy that this protocol engenders. (B) Training conditions.
There were three experiments, each preceded by a common set of 8 d of
pretraining. Drugs were infused into the hippocampus at various times in
relation to trials 1 and 2 as described.
Dopamine and memory persistence
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ment 1, with particularly effective performance displayed during
the last 2 d (shaded gray). The conventional measure of escape
latency is plotted. On each day, the memory delay between trials
1 and 2 was 20 min for half the rats, and 6 h for the others. These
intervals were counterbalanced across days, but pooled data are
plotted in Figure 2. Mean savings in escape latency between trials
1 and 2 over the 8 d of pretraining did not differ between the two
memory delays (t = 0.95, df = 22; P > 0.3). Task acquisition fol-
lowed a similar pattern in Experiments 2 and 3 (data not shown).
As the drug treatment in the test phase of each experiment
affected swim speed, the remaining data is analyzed in terms of
both swim speed and path length (rather than escape latency), in
accordance with current convention regarding the optimum way
to present watermaze data. To facilitate comparisons across ex-
periments, a performance measure was also calculated, in which
path lengths were normalized to the mean trial 1 path lengths in
the appropriate control condition (i.e., no infusion, or
aCSF = 100%). In this way, relative increases and decreases of
path length induced by SCH23390 at various memory delays
were readily observed, as well as absolute changes in path length
in measures of savings.
Experiment 1: A delay-dependent memory deficit
following intrahippocampal infusions of SCH23390
In Experiment 1, the testing phase was procedurally identical to
pretraining, except that rats received a 5-min bilateral intrahip-
pocampal infusion of either aCSF or SCH23390, finishing 15 min
before trial 1 of each day (Fig. 1B). Figure 3A shows normalized
path length across trials for the two memory delays after trial 1
(20 min on the left, 6 h on the right). For each animal, every
combination of drug and ITI was repeated twice (see Materials
and Methods). These two values were averaged for each of the
four trials. Data were then averaged across all 23 rats, and a be-
tween-subjects standard error calculated, to produce each of the
four acquisition curves shown in Figure 3A. Both SCH23390- and
aCSF-treated rats exhibited good memory for the platform loca-
tion in trial 2 after 20 min, but the drug-treated group was im-
paired after a 6-h memory delay. An analysis of variance of path
lengths in trials 1 and 2 revealed a significant triple interaction of
trial, drug treatment, and memory delay (F(1,22) = 4.90; P < 0.05).
A separate ANOVA of performance at the 20-min delay revealed
a significant overall improvement between trials 1 and 2
(F(1,22) = 14.8; P = 0.001), but no interaction between trial and
drug treatment (F(1,22) = 1.07; P > 0.3). The trend toward a
SCH23390-induced impairment in trial 2 did not reach signifi-
cance (F(1,22) = 3.13; 0.1 > P > 0.05). In contrast, at the 6-h
memory delay a highly significant interaction of trial and drug
treatment was observed (F(1,22) = 20.1; P < 0.001). Whereas aCSF-
treated rats improved between trials 1 and 2 (t = 4.04, df = 22;
P = 0.002), no change in performance between trials was evident
following the administration of SCH23390 (t = 1.56, df = 22;
P > 0.2).
A separate analysis was conducted of absolute savings in
path length (in meters) between trials 1 and 2 as a function of
memory delay (20 min or 6 h). This also highlights the delay-
dependent effects of treatment with SCH23390 (see Fig. 3B). An
overall ANOVA revealed a significant interaction between drug
treatment and memory delay (F(1,22) = 4.90; P < 0.05). Perfor-
mance was insensitive to delay following aCSF infusion (t = 0.85,
df = 22; P > 0.9) but significant delay-dependent forgetting was
evident after treatment with SCH23390 (t = 3.04, df = 22;
P < 0.02). The savings in absolute path length in the two drug
conditions did not differ at the 20-min interval (t = 1.04, df = 22;
P > 0.6), but a clear difference was evident after a 6 h-delay
(t = 4.48, df = 22; P < 0.001). In fact, at a 6-h memory delay, the
performance of SCH23390-treated rats did not differ from chance
(t = 1.56, df = 22; P > 0.1; one-sample t-test). Upon return to the
short interval between trials 2 and 3, and then 3 and 4, the
performance of the animals in the SCH23390 6-h delay condi-
tion reached levels equivalent to those of aCSF-treated controls
(F(1,22) = 2.74; P > 0.1). This indicates that drug-treated animals
were able to remember the position of the platform onto which
they escaped in trial 2 (over 6 h after drug infusion) and so per-
form well in trials 3 and 4.
Measurement of swim speed revealed a small but transient
decline following treatment with SCH23390 (Fig. 3C). This effect
appeared predominantly in trial 1, with little effect on subse-
quent trials, and sometimes resulted in slower swim speeds. An
analysis of variance of swim speeds across all trials revealed a
significant interaction between drug treatment and trial
(F(3,66) = 5.54; P < 0.05). Pairwise comparisons showed that swim
speeds were significantly lower in trial 1 following SCH23390
treatment, compared with aCSF (F(1,22) = 35.8; P < 0.001), further
justifying our use of path length rather than escape latency for
the main data measures. The impairment was short-lasting, with
the difference in swim speed being no more than a trend in trial
2 (F(1,22) = 4.30; 0.1 > P > 0.05).
Experiment 2: SCH23390 has no effect on memory
at a long delay when given after trial 1
We then sought to establish whether the effect observed in Ex-
periment 1 was due to a requirement for hippocampal dopamine
receptor activation during the encoding of the novel platform
position or during the subsequent processing of this information
after acquisition. In Experiment 2, following the usual pretrain-
ing sessions (as shown in Fig. 2), the animals received a 5-min
intrahippocampal infusion of either aCSF or SCH23390 between
10 and 15 min after trial 1 on each of the 8 d of further training.
Only the 6-h memory delay was used.
The key finding was that when infused with SCH23390, the
animals showed good memory for the platform location in trial
2 conducted 6 h later. Performance was indistinguishable from
that shown by these same animals on aCSF-infusion days. Figure
4A shows normalized path lengths averaged across the 4 d on
which the relevant drug was administered. An analysis of vari-
Figure 2. Pretraining. Acquisition of delayed matching-to-place. Abso-
lute escape latency across the 8 d of pretraining during Experiment 1.
Note the gradual acquisition of an effective win-stay strategy character-
ized by, over the last 2 d (shaded), a striking reduction in escape latency
between trials 1 and 2 of each day. Escape latency in trial 1 remains stable
at ca 60 sec, reflecting the novel daily location of the hidden platform.
Means  1 SEM.
O ’Carroll et al.
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ance of path lengths in trials 1 and 2 revealed no significant
effect of drug treatment (F < 1), and no interaction between drug
treatment and trial (F < 1). This finding is supported by an analy-
sis of savings in path length between trials 1 and 2 for both
groups. As shown in Figure 4B, there was no difference in savings
between the SCH23390 and aCSF groups (t = 0.33, df = 7;
P > 0.7).
Normalization of path lengths offered the opportunity to
compare across experiments. Path length in trial 2 of Experiment
2, after a 6-h ITI, was ≅60% of that in trial 1 for both the aCSF and
SCH23390 conditions. In Experiment 1, the same value was ob-
tained following aCSF infusions given prior to trial 1, whereas the
SCH23390 condition was characterized by a much longer mean
path length in trial 2 (112%). Thus, there is a dramatically dif-
ferent effect of giving SCH23390 at a point 15 min before or 15
min after the memory-encoding trial on
memory measured 6 h later.
Experiment 3: Absence of state-
dependent effects of SCH23390 on
retention after a long delay
State-dependent memory is a phenom-
enon in which the retrieval of informa-
tion is possible only if the subject expe-
riences the same sensory context and
physiological state as that present dur-
ing the encoding phase. One possible ex-
planation for the drug-induced retrieval
deficit observed in Experiment 1 at the
6-h interval is that the drug was no
longer present when the rats were placed
back into the pool in trial 2. In contrast,
at the 20-min interval, the drug would
almost certainly have been present in
both trial 1 and trial 2, maintaining the
same physiological state during both the
encoding and retrieval phases of the ex-
periment. Experiment 3 was conducted
in order to address this alternative pos-
sibility; 15 min before trial 1 of each day,
animals received an intrahippocampal
infusion of either aCSF or SCH23390; a
second infusion, always of SCH23390,
was made 15 min prior to trial 2 (see Fig.
1B). The interval between trials 1 and 2
was always 6 h. Days when animals had
no infusions were interleaved between
days with infusions to provide an inter-
nal within-subjects control for baseline
performance on the task. A counterbal-
anced sequence of the two conditions
continued for 8 d.
The key finding was that when ani-
mals received intrahippocampal infu-
sions of SCH23390 both 15 min before
trial 1 and 15 min before trial 2, they
showed poor memory (at 6 h) for the
platform location in trial 2 (Fig. 5A).
However, when the animals were in-
jected with aCSF 15 min before trial 1,
and then given SCH23390 before trial 2,
retention was normal; performance was
equivalent to that observed on the “no
infusion” days. An ANOVA of perfor-
mance in trials 1 and 2 revealed a signifi-
cant interaction between treatment and trial (F(2,14) = 5.14;
P < 0.05), with no significant improvement between trials in the
SCH23390/SCH23390 condition (t = 0.58, df = 7; P > 0.9), but a
significant reduction in path length on aCSF/SCH23390
(t = 3.64, df = 7; P < 0.05). An ANOVA of savings data (Fig. 5B)
revealed a main effect of drug treatment condition (F(2,14) = 6.37;
P < 0.02), with significantly higher savings in the aCSF/
SCH23390 condition relative to the SCH23390/SCH23390 con-
dition (t = 5.94, df = 7; P = 0.001), in which no significant savings
were observed (t = 0.58, df = 7; P > 0.5; one-sample t-test).
Normalization again allowed interexperiment comparisons.
In Experiment 3, performance in trial 2 (ca 45% of trial 1 path
length) was slightly better than in Experiments 1 and 2, but the
overall pattern shown across groups was comparable. Path length
in trial 2 in the SCH23390/SCH23390 condition of Experiment 3
Figure 3. Experiment 1. (A) Drug injections prior to trial 1—impact of memory delay. Normalized
path length averaged across days during the drug-infusion phase, showing performance across the
four trials of each day (n = 23). A delay-dependent deficit is apparent, with the condition in which the
animals received SCH23390 and a long memory delay resulting in no memory in trial 2 of each day.
The syringes’ symbols and dotted lines indicate the time of drug infusion. (B) Savings in path length
between trials 1 and 2. The change in performance between trials 1 and 2 (i.e., savings) is plotted in
terms of absolute path length. These data show exactly the same pattern as in the normalized scores.
(C) Swim speed. The drug did transiently decrease swim speeds, but the effect is only apparent in trial
1 of each day, scheduled 15 min after the intrahippocampal drug infusion. Means  1 SEM.
Dopamine and memory persistence
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was ≅91% of that in trial 1 (compared with a ≅39% for the aCSF/
SCH23390 condition), a deficit of similar magnitude to that
found in Experiment 1.
Histology
Cannulae were correctly placed within the dorsal hippocampal
formation in all cases; a representative example of Nissl-stained
brain sections is shown in Figure 6A. Infusion sites for all 39 rats
tested in Experiments 1–3 are illustrated in Figure 6B, mapped
onto successive coronal sections of the Paxinos and Watson
(1998) atlas. The tips of all infusion cannulae were correctly lo-
cated in the hippocampal formation.
Discussion
The main finding of these experiments is that bilateral intrahip-
pocampal infusion of the D1/D5 receptor antagonist SCH23390
produced a delay-dependent impairment of spatial memory.
There was a modest trend, but no significant impairment of
memory after a short delay (20 min), arguing against a substan-
tial contribution of dopaminergic activation to memory strength
under the present circumstances, but a clear loss of spatial
memory after 6 h, implying an effect on persistence (Experiment
1). Moreover, the effect of SCH23390 on performance after the
6-h interval was specific to it being present during the encoding
of the platform location during trial 1, as no effects on perfor-
mance after the 6-h interval were observed when the drug was
infused after trial 1 (Experiment 2). The impairment seen at 6 h
was not due to state dependency (Experiment 3) as a deficit was
also seen if drug infusions occurred prior to both the encoding
trial (trial 1) and the first memory retrieval trial (trial 2). The
findings of Experiment 3 also replicate the delay-dependent ef-
fects of dopamine receptor blockade observed in Experiment 1:
Long-term memory in trial 2 (6-h ITI) was impaired following an
infusion of SCH23390 before trial 1, but short-term memory be-
tween trials 2 and 3 (30-sec ITI) was unimpaired following a sec-
ond drug infusion before trial 2.
Infusion of SCH23390: Dose, timing, and side effects
The concentration of SCH23390 used in the present study (5 µg
in 1 µL) was based on the highest dose infused into the prefrontal
cortex in the study by Seamans et al. (1998), but is higher than
concentrations typically infused intrahippocampally (e.g., Berna-
beu et al. 1997) (maximum dose = 5 µg per hippocampus). In the
absence of microdialysis data (see Davis et al. 1992), it is difficult
or impossible to estimate the effective hippocampal concentra-
tion of a drug following an acute intrahippocampal infusion.
Accordingly, we cannot exclude the possibility that SCH23390
has agonist actions at 5-HT2a and c receptors at the concentra-
tion used (see Porter et al. 1999). However, the activation of these
receptors has been implicated in the facilitation of hippocampus-
dependent memory (Buhot et al. 2000; Harvey 2003), in contrast
to the findings reported here.
In the present study, drug infusion was associated with a
very mild hypokinesia and a reduction in swim speed in trial 1,
but these effects were transient, dissipated rapidly, and were
largely absent by trial 2. A sensorimotor account of the effects of
SCH23390 on retention performance is therefore unlikely. More
tellingly, such an account would be inconsistent with our find-
ing of better memory at a short delay after infusion before trial 1
(Experiment 1; 20-min memory delay), when the drug was most
likely still present, compared with the impairment seen at the
long delay (Experiment 1; 6-h memory delay). This argument is
Figure 4. Experiment 2. (A) Drug injections after trial 1 (6-h memory
delay). Normalized path length averaged across days during the drug-
infusion phase, showing performance across the four trials of each day
(n = 8). No impairment is observed in the SCH23390 condition with the
drug infusion occurring 15 min after trial 1. (B) Savings in path length
between trials 1 and 2. The data show an equivalent level of absolute
savings in path length in both conditions. Means  1 SEM.
Figure 5. Experiment 3. (A) Drug injection prior to trials 1 and 2 (6-h
memory delay). Normalized path length averaged across days during the
drug-infusion phase, showing performance across the four trials of each
day (n = 8). A clear interaction is apparent to the effect that memory in
trial 2 is impaired when the drug is infused on two occasions each day—
before both trials 1 and 2. Conversely, the group receiving aCSF initially,
but drug later, showed good memory. The impairment in Experiment 1
cannot be due to state dependency. (B) Savings in path length between
trials 1 and 2. The same pattern is apparent in the absolute path-length
data, with only the group having SCH23390 present at the time of en-
coding showing a memory deficit. Means  1 SEM.
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further supported by the absence of an impairment following
drug infusion prior to retention testing in Experiment 3 when
aCSF was given prior to trial 1. Nonetheless, the differential effect
of SCH23390 infused before or after trial 1 raises the possibility
that the drug affects perceptual or attentional processes during
encoding, rather than memory per se. However, the use of two
different memory-delay intervals and the finding that the drug
affects long-term but not short-term memory makes this un-
likely; a disruption of such processes should cause a delay-
independent impairment; this was not observed.
State-dependent learning is a phenomenon in which the
retrieval of newly acquired information is facilitated if the sub-
ject is in the same sensory context and physiological state as that
during the encoding phase (Overton 1964). By infusing animals
just prior to both trial 1 and trial 2 in Experiment 3, we were also
able to address the possibility that the animals trained with the
20-min ITI in Experiment 1 were still influenced by the drug in
trial 2 and thus able, on state-dependent grounds, to perform
well. The drug would have washed out in the 6-h condition,
leaving the animals in a different physiological “state” during
trial 2. The findings of Experiment 3 revealed that the only group
of animals displaying poor retention was that infused twice with
SCH23390. This is inconsistent with the effects being due to
state-dependency.
It is interesting that the 6-h drug treatment condition ex-
hibits such a marked improvement in performance between trials
2 and 3, with asymptotic performance reached after a single re-
exposure to the platform location. Although a failure of retrieval
in trial 2 cannot be ruled out, this may not be the most likely
explanation. First, a state-dependent failure of retrieval in trial 2
is ruled out by the results of Experiment 3. Second, it is possible
that some time-limited effect of the drug infusion procedure,
perhaps caused by stress or the change in context, might have
impaired subsequent learning during trial 2 at the 20-min ITI.
This might explain the poorer savings between trials 2 and 3 in
both drug and aCSF conditions following the 20-min ITI, com-
pared with the 6-h ITI. And in Experiment 3, when infusions
were always given before trial 2 as well as trial 1, performance in
trial 3 in the 6-h drug/drug-treated condition was no better than
would be expected based on the one-trial improvement observed
in the other conditions, and slightly worse than that observed in
Experiment 1.
Relationship of these findings to the synaptic tagging
and capture hypothesis
Long-term potentiation (LTP), an activity-dependent persistent
increase in synaptic strength (Bliss and Lømo 1973), is the pre-
vailing model of hippocampal learning-related synaptic plastic-
ity, and the cornerstone of the generic “synaptic plasticity and
memory” hypothesis. (Goelet et al. 1986; Bliss and Collingridge
1993; Martin et al. 2000; Martin and Morris 2002). However, an
efficient memory system must retain relevant information selec-
tively, while permitting the decay of irrelevant memory traces
(McGaugh 2000). As discussed in the introduction, novelty has
been implicated in the selection of hippocampal memory traces
to be stored for long or short periods of time, but other factors
such as stress and reward are also known to modulate hippocam-
pal memory (McGaugh 2004; Wittmann et al. 2005; Adcock et al.
2006; Shors 2006), perhaps via their impact on synaptic plasticity
(Seidenbecher et al. 1995, 1997; Xu et al. 1998b; Richter-Levin
and Akirav 2003; Diamond et al. 2005; Korz and Frey 2005;
Ahmed et al. 2006; Kavushansky et al. 2006). In one variant of
this idea, the “synaptic tagging and capture” (STC) hypothesis
(Frey and Morris 1997, 1998; Kelleher III et al. 2004), mecha-
nisms underlying the persistence of LTP in the hippocampus
involve the intersection of two dissociable events: the local set-
Figure 6. Histology. (A) Photomicrographs showing representative
cannulae tracks into the dorsal hippocampus on each side of the brain.
(B) Plots of the locations of the tips of the cannulae (n = 39 per hippo-
campus) as revealed in Nissl-stained brain sections. Plots of the locations
of the tips of the cannulae (n = 39 per hippocampus) as revealed in
Nissl-stained brain sections. Infusion sites are marked on the appropriate
section of a stereotaxic brain atlas (reprinted with permission from
Elsevier © 1998, Paxinos and Watson 1998 [Figs. 35–39]).
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ting of tags at activated glutamatergic synapses, followed by the
sequestration of plasticity proteins newly synthesized in re-
sponse to the activation of neuromodulatory inputs—and the
subsequent activation of metabotropic cAMP-coupled receptors.
Neuromodulatory inputs that regulate hippocampal synaptic
plasticity include dopaminergic afferents to CA1 (see Introduc-
tion), noradrenergic inputs to the dentate gyrus (Straube et al.
2003; Harley 2004; Almaguer-Melian et al. 2005), and direct or
indirect projections from other brain areas, such as the basolat-
eral amygdala (Abe 2001; Frey et al. 2001; Almaguer-Melian et al.
2003; Richter-Levin and Akirav 2003; McGaugh 2004;
Roozendaal et al. 2006). Once information is computed as novel
or motivationally significant, feedback from neuromodulatory
inputs such as those emanating from the VTA may rapidly influ-
ence the subsequent storage of such information. For example,
Lisman and Otmakhova (2001) and Lisman and Grace (2005)
suggest that synaptic plasticity following the exposure to and
computation of novelty is critical to the formation of hippocam-
pus-dependent memory.
Although there is some evidence that activation of hippo-
campal dopamine receptors with D1/D5 receptor agonists can
alone be sufficient to induce late-LTP in hippocampal slices
(Huang and Kandel 1995), more recent evidence points to the
neuromodulatory effect that dopamine exerts on glutamate-
induced events (Sajikumar and Frey 2004). Specifically, there is
growing evidence for multilevel functional interactions between
D1 and ionotropic glutamate receptors (e.g., Yang 2000; for re-
view, see Cepeda and Levine 2006). It seems that the conditions
necessary for “synaptic tagging” to occur require simultaneous
coactivation of both D1/D5 and NMDA receptors to trigger the
up-regulation of protein synthesis (O’Carroll and Morris 2004) or
sufficient increases in intracellular cAMP concentrations through
synergistic interaction between the two classes of receptor
(Mockett et al. 2004). According to this view, the primary physi-
ological impact of dopaminergic activity is not on the strength of
potentiation directly, but in contributing to the triggering of cel-
lular consolidation processes immediately after encoding (al-
though effects on LTP magnitude should not be discounted) (see
Li et al. 2003). These ideas are compatible with the Lisman and
Grace (2005) model of VTA-hippocampal interactions, and are
consistent with our observation that SCH23390 was only effec-
tive in blocking memory when given at the time of trial 1. If
SCH23390 blocked a chronic or constitutive effect of D1/D5 re-
ceptor activity on downstream signal-transduction pathways
that enable memory persistence, its infusion 15 min after trial 1
might still have limited the persistence of memory. This was not
observed. Such findings are also consistent with Kentros et al.’s
(2004) data revealing opposite effects of a dopamine agonist
(SKF38392) and antagonist (SCH23390) on place field stability,
although interpreted by these investigators more in attentional
terms. It may seem surprising that D1/D5 blockade as little as 15
min after trial 1 has no effect on memory, but this lack of effect
is consistent with the need for dopamine/NMDA receptor inter-
actions at the time of encoding, whether to affect spatial memory
or place field stability. More direct evidence in support of the STC
framework would include studies showing the induction of long-
term memory during blockade of D1/D5 receptors if they had
earlier been coactivated with glutamatergic afferent stimulation
in the same neurons. Separate studies are underway to investigate
this paradoxical prediction.
“Novelty” may have multiple physiological
consequences
It is not yet clear what aspect of the rats’ experience during trial
1 triggers the activation of dopamine receptors necessary for
long-term memory formation. Relevant factors might include
unexpected reward upon encountering the escape platform, an
increase in arousal induced by immersion in water, or the expe-
rience of escape in a novel spatial location. Although its rel-
evance to the present data remains uncertain, there is growing
interest in the role of novelty in synaptic plasticity and memory.
For example, exposure to novelty can facilitate the persistence of
LTP as well as LTD—even in strains of rat in which LTD is nor-
mally difficult to observe (Manahan-Vaughan and Braunewell
1999; Kemp and Manahan-Vaughan 2004), an effect that is pre-
vented by the administration of SCH23390 (Lemon and Mana-
han-Vaughan 2006). These findings are consistent with the ef-
fects of dopamine receptor activation on late-LTP and LTD (Saji-
kumar and Frey 2004), and support the notion that memory
formation requires both down- and up-regulation of synaptic
strength (Willshaw and Dayan 1990). Exploration of a novel en-
vironment can also reverse LTP that has been recently induced in
freely moving animals (Xu et al. 1998a), perhaps owing to the
novelty-associated increase in  activity (6–8 Hz) in the hippo-
campus; an EEG pattern may supply the low-frequency stimula-
tion necessary for depotentiation. However, the pharmacological
activation of dopamine receptors has been reported to block de-
potentiation, a phenomenon that has been suggested to protect
important memory traces from interference (Otmakhova and Lis-
man 1998; Kulla and Manahan-Vaughan 2000). In thinking
about this apparent contradiction, it may be significant that dif-
ferent forms of novelty can influence synaptic plasticity in dis-
tinct ways (Kemp and Manahan-Vaughan 2004). To better un-
derstand the relationship between the present findings and the
existing literature concerning novelty and the modulation of
synaptic plasticity, further studies exploring the interactions be-
tween exposure to a novel platform location and the induction
and persistence of synaptic changes will be required.
Summary
The present data suggest that the activation of hippocampal do-
pamine receptors is necessary for the formation of long-term spa-
tial memory. We hypothesize that the firing of midbrain dopa-
minergic neurons—in response either to the unexpected reward
or the spatial novelty of finding an escape platform in a new
location—leads to hippocampal dopamine release and the acti-
vation of D1/D5 receptors in conjunction with the glutamatergic
activation of NMDA receptors. The downstream consequences of
this activity might include the up-regulation of protein synthe-
sis, and the subsequent stabilization of synaptic changes at syn-
apses “tagged” by glutamatergic stimulation. In the presence of a
D1/D5 receptor antagonist, this selective stabilization mecha-
nism would fail, resulting in the observed loss of long-term
memory.
Materials and Methods
Animals
Adult male Lister hooded rats (250–500 g) were used as subjects.
They were given ad libitum access to food and water and were
maintained on a 12-h light/12-h dark cycle. The animals’ care
and maintenance and all experimental procedures were carried
out in accordance with UK Home Office regulations under
Project License no. 603241.
Surgery
Prior to the implantation of cannulae, the rats were anesthetized
with Avertin (tribromoethanol) and placed in a stereotaxic frame
(Kopf) using a flat skull position. Guide cannulae (Plastics One;
outer diameter = 0.46 mm) were implanted bilaterally into the
dorsal hippocampus (coordinates from bregma: AP = 4.5;
O ’Carroll et al.
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Lat. = 3.0 mm; DV (from dura) =2.5 mm). These were fixed in
place using dental cement, and the headcap secured to the skull
using jewelers’ screws. To prevent blockage or infection, dummy
cannulae (stylets; outer diameter = 0.20 mm; 0.5-mm protrusion
from end of guide cannulae) were inserted into the guides. Post-
operative analgesia was given (Rimadyl, 5 mg/kg by subcutane-
ous injection), and rats were given at least 7 d to recover before
the start of behavioral testing.
Watermaze
Behavioral testing was carried out in an open-field watermaze, 2
m in diameter, and filled with water at 25 1°C made opaque by
the addition of 200 mL of latex solution. The pool was located in
the center of a room containing prominent extramaze cues
(poster, metal racks, etc.). The rats were placed into the water,
facing the pool walls, and allowed to escape onto a hidden plat-
form, 12 cm in diameter, whose top surface was submerged 1.5
cm below the water surface. The animals’ swimming was moni-
tored by an overhead video camera connected to a video recorder
and a computer running custom-written Watermaze software
(Actimetrics) that digitizes the path taken by the rat and com-
putes various behavioral measures such as escape latency, path
length, and swim speed.
Pretraining
In all experiments, rats were given 8 d of pretraining with four
trials per day. The starting point for each trial was north, south,
east, or west, varying in a quasirandom sequence, with rats
placed gently into the water facing the side-walls. During pre-
training, the hidden platform was located, on successive days, in
one of eight possible locations within the pool. The platform
location was changed between days according to a quasirandom
schedule, and locations were never repeated (Fig. 1A). Each rat
was randomly assigned to one of two counterbalanced platform
location sequences, each of which was a mirror-image of the
other. All trials ended with a 30-sec stay on the platform, during
which the rat could turn, rear, and otherwise sample its location
in space. After removal from the pool, the intertrial interval (ITI)
between trials 1 and 2 was either 20 min or 6 h (see below);
subsequent ITIs were always 15 sec.
Drug preparation
A total of 16 mg of powdered SCH23390 was dissolved in 3.2 mL
of sterile, millipore-filtered aCSF (in millimolar: 150 Na+, 3 K+,
1.4 Ca2+, 0.8 Mg2+, 155 Cl, 0.2 H2PO4
, 0.8 HPO4
2, in pyro-
gen-free water at pH 7.2) yielding a concentration of 5 mg/mL
(15.42 mM) This solution was vortexed and gently sonicated,
divided into 500-µL aliquots, and stored at –20°C prior to use.
Drug infusion
Prior to daily infusions, the dummy cannulae were removed, and
injection needles were inserted (outer diameter = 0.20 mm).
These protruded 0.5 mm from the ends of the guide cannulae
(i.e., infusion site =3.0 mm from dura), and were connected
via plastic tubing to SGE syringes mounted in a syringe driver.
SCH23390 or aCSF (1 µL/side) was infused at a rate of 0.2 µL/min
over 5 min, and the needles left in place for a further 2 min after
infusion to avoid back-flow. Finally, the dummy cannulae were
replaced.
Experiment 1: Does SCH23390 infusion before encoding
affect the persistence of memory?
Following pretraining, 23 animals were tested over eight con-
secutive days with four trials per day, exactly as described for
pretraining. The hidden platform was located, on successive
days, in one of eight possible novel locations within the pool that
differed from those used in pretraining. The memory delay be-
tween trials 1 and 2 was either 20 min or 6 h, but always 30 sec
for the remaining trials. Across the 8 d, there were four infusions
of aCSF and four infusions of SCH23390, each lasting 5 min, and
finishing 15 min before trial 1 (Fig. 1B). Of the four infusions of
each drug, two were made before a 20-min ITI, and two were
made before a 6-h ITI. Drug treatments and ITIs were varied in a
counterbalanced manner both within and across days, according
to a partial Latin-square design.
Experiment 2: Does SCH23390 infusion after encoding
affect the persistence of memory?
In Experiment 2, the memory delay between trials 1 and 2 was
always 6 h. The animals (n = 8) received 4 d of aCSF infusion and
4 d of SCH23390 infusion in a counterbalanced manner, with
each 5-min infusion finishing 15 min after trial 1 (i.e., 5 h and 45
min prior to trial 2; Fig. 1B). In other respects, training was con-
ducted as in Experiment 1.
Experiment 3: Does SCH23390 infusion affect memory
due to state dependency?
In Experiment 3, the memory delay between trials 1 and 2 was
again always 6 h. Animals (n = 8) received a 5-min intrahippo-
campal infusion of either aCSF or SCH23390, finishing 15 min
before trial 1 of each day; a second infusion, always of SCH23390,
finished 15 min prior to trial 2. After each infusion day, the
animals were tested for a further day without receiving any in-
jections. The drug and noninfusion conditions alternated, pro-
viding an internal within-subjects control for baseline perfor-
mance on the task. These treatments continued for 8 d in a coun-
terbalanced order, with a total of two SCH23390/SCH23390 days,
two aCSF/SCH23390 days, and four no-infusion days for each rat.
In all other respects, training was conducted as in Experiment 1.
Histology
At the end of the experiment, all animals were cardiac perfused
with 0.9% saline followed by 10% formalin. Their brains were
removed, placed in formalin, and 20-µm sections were cut using
a cryostat. These sections were stained using cresyl violet and
examined under a light microscope. For each brain, the infusion
site was plotted by determining the deepest point at which tissue
damage was evident, and marking this location on the appropri-
ate coronal section taken from the Paxinos and Watson (1998)
atlas.
Statistics
All numerical data are presented as mean SEM. Following an
Analysis of Variance (ANOVA), pairwise comparisons were al-
ways conducted using Student’s paired-sample t-test with Bon-
ferroni correction for multiple comparisons, if appropriate. As
described in the text, the main analyses were conducted using a
measure of normalized path length that aided comparison across
studies. Some data are also reported using escape latency (pre-
training) and absolute savings in path length (all experiments).
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